ArticleFrontiers in oncology2026
A case series of primary urinary tract neuroendocrine neoplasms.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neuroendocrine neoplasms (NENs) are a heterogeneous group of tumors that originate from neuroendocrine cells. They are common in the digestive system (such as the stomach, intestines, and pancreas) and the respiratory system, but they are rare in the urinary system, comprising less than 1%-2% of urinary malignancies. These tumors typically lack specific clinical symptoms and are usually diagnosed through postoperative pathological examinations. Due to their rarity, the clinical awareness of NENs remains insufficient in the community. Methods: Clinical data of 10 patients diagnosed with urinary tract neuroendocrine neoplasms (UT-NENs) were retrospectively collected and analyzed. We summarized their clinical characteristics and treatment outcomes, with the aim to improve our understanding of urinary tract NENs and further optimize personalized therapeutic strategies for these rare tumors. Result: In our study, 4 out of 10 patients were admitted for hematuria. Seven out of 10 patients had lesions in the bladder. Five of 6 cases with NEN muscularis propria invasion occurred in the bladder. All 3 deceased patients had bladder NEN. None of them received postoperative radiotherapy and chemotherapy. Five out of 6 surviving patients received postoperative radiotherapy and chemotherapy. Conclusion: Hematuria is the main symptom in UT-NENs. The bladder is the most common location of UT-NENs, while bladder lesions are more likely to present as poorly-differentiated neuroendocrine carcinoma. In the present case series, patients who received postoperative radiotherapy and chemotherapy showed a trend toward better long-term prognosis and survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.